title: Oncolytic measles virus retargeting by ligand display.
abstract: Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them measles virus (MV) vaccine strains have emerged as a promising oncolytic platform. Retargeted MV strains deriving from the Edmonston vaccine lineage (MV-Edm) have shown comparable antitumor efficacy to unmodified strains against receptor expressing tumor cells with improved therapeutic index. Here, we describe the construction, rescue, amplification, and titration of fully retargeted MV-Edm derivatives displaying tumor specific receptor binding ligands on the viral surface in combination with H protein CD46 and SLAM entry ablating mutations.
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Pavlos
authors.initials: P
authors.lastname: Msaouel
authors.forename: Ianko D
authors.initials: ID
authors.lastname: Iankov
authors.forename: Cory
authors.initials: C
authors.lastname: Allen
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Russell
authors.forename: Evanthia
authors.initials: E
authors.lastname: Galanis
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D005822:Genetic Vectors; D006801:Humans; D008024:Ligands; D008458:Measles Vaccine; D008459:Measles virus / Q000235:genetics*; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics*; D014709:Vero Cells; D014779:Virus Replication / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D008024:Ligands; D008458:Measles Vaccine